Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Buy
55
RDY Quote, Financials, Valuation and Earnings
Last price:
$14.20
Seasonality move
:
4.97%
Day range:
$14.10 - $14.21
52-week range:
$12.26 - $16.17
Dividend yield:
0.66%
P/E ratio:
17.37x
P/S ratio:
2.98x
P/B ratio:
2.93x
Volume:
816.3K
Avg. volume:
1.1M
1-year change:
-1.94%
Market cap:
$11.8B
Revenue:
$3.9B
EPS (TTM):
$0.82
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$983.7M | $0.19 | -2.63% | 3.83% | $14.58 |
|
ALVO
Alvotech
|
$117.2M | -$0.03 | 9.08% | -87.15% | $25.60 |
|
CCM
Concord Medical Services Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
ESPR
Esperion Therapeutics, Inc.
|
$77.2M | -$0.08 | 138.3% | -48.14% | $6.50 |
|
NVO
Novo Nordisk A/S
|
$11.9B | $0.66 | -1.21% | 0.25% | $53.27 |
|
TEVA
Teva Pharmaceutical Industries Ltd.
|
$4.3B | $0.67 | 3.94% | 71.31% | $28.61 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$14.19 | $14.58 | $11.8B | 17.37x | $0.09 | 0.66% | 2.98x |
|
ALVO
Alvotech
|
$5.47 | $25.60 | $1.7B | 23.75x | $0.00 | 0% | 3.01x |
|
CCM
Concord Medical Services Holdings Ltd.
|
$3.99 | -- | $17.3M | -- | $0.00 | 0% | 0.34x |
|
ESPR
Esperion Therapeutics, Inc.
|
$3.73 | $6.50 | $884.3M | -- | $0.00 | 0% | 2.42x |
|
NVO
Novo Nordisk A/S
|
$47.86 | $53.27 | $212.7B | 13.94x | $0.58 | 3.61% | 4.57x |
|
TEVA
Teva Pharmaceutical Industries Ltd.
|
$28.46 | $28.61 | $32.7B | 46.41x | $0.00 | 0% | 1.95x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Ltd.
|
14.04% | -0.469 | 5.65% | 1.12x |
|
ALVO
Alvotech
|
115.99% | 2.339 | 50.24% | 0.54x |
|
CCM
Concord Medical Services Holdings Ltd.
|
273.84% | -1.533 | 77.28% | 0.19x |
|
ESPR
Esperion Therapeutics, Inc.
|
408.15% | 2.653 | 109.82% | 0.65x |
|
NVO
Novo Nordisk A/S
|
37.33% | 1.647 | 6.46% | 0.46x |
|
TEVA
Teva Pharmaceutical Industries Ltd.
|
70.19% | -0.313 | 73.66% | 0.53x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$517.5M | $178.5M | 14.9% | 17.11% | 17.71% | $49.2M |
|
ALVO
Alvotech
|
$78.7M | $1.2M | 7.33% | -- | 1.05% | -$84M |
|
CCM
Concord Medical Services Holdings Ltd.
|
-- | -- | -7.49% | -19.78% | -- | -- |
|
ESPR
Esperion Therapeutics, Inc.
|
$46M | -$10M | -60.77% | -- | -11.41% | -$23.9M |
|
NVO
Novo Nordisk A/S
|
$8.9B | $3.7B | 41.85% | 68.76% | 31.74% | $4.8B |
|
TEVA
Teva Pharmaceutical Industries Ltd.
|
$2.3B | $1.1B | 2.75% | 10.27% | 23.84% | -$53M |
Dr. Reddy's Laboratories Ltd. vs. Competitors
-
Which has Higher Returns RDY or ALVO?
Alvotech has a net margin of 16.2% compared to Dr. Reddy's Laboratories Ltd.'s net margin of -4.62%. Dr. Reddy's Laboratories Ltd.'s return on equity of 17.11% beat Alvotech's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.51.32% $0.20 $4.7B ALVOAlvotech69.22% -$0.02 $1.1B -
What do Analysts Say About RDY or ALVO?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.58, signalling upside risk potential of 2.74%. On the other hand Alvotech has an analysts' consensus of $25.60 which suggests that it could grow by 368.01%. Given that Alvotech has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Alvotech is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 ALVOAlvotech3 1 0 -
Is RDY or ALVO More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.391, which suggesting that the stock is 60.915% less volatile than S&P 500. In comparison Alvotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RDY or ALVO?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.66%. Alvotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Alvotech pays out -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or ALVO?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $1B, which are larger than Alvotech quarterly revenues of $113.7M. Dr. Reddy's Laboratories Ltd.'s net income of $163.4M is higher than Alvotech's net income of -$5.3M. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 17.37x while Alvotech's PE ratio is 23.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.98x versus 3.01x for Alvotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.98x 17.37x $1B $163.4M ALVOAlvotech3.01x 23.75x $113.7M -$5.3M
-
Which has Higher Returns RDY or CCM?
Concord Medical Services Holdings Ltd. has a net margin of 16.2% compared to Dr. Reddy's Laboratories Ltd.'s net margin of --. Dr. Reddy's Laboratories Ltd.'s return on equity of 17.11% beat Concord Medical Services Holdings Ltd.'s return on equity of -19.78%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.51.32% $0.20 $4.7B CCMConcord Medical Services Holdings Ltd.-- -- $727.8M -
What do Analysts Say About RDY or CCM?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.58, signalling upside risk potential of 2.74%. On the other hand Concord Medical Services Holdings Ltd. has an analysts' consensus of -- which suggests that it could grow by 200.75%. Given that Concord Medical Services Holdings Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Concord Medical Services Holdings Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 CCMConcord Medical Services Holdings Ltd.0 0 0 -
Is RDY or CCM More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.391, which suggesting that the stock is 60.915% less volatile than S&P 500. In comparison Concord Medical Services Holdings Ltd. has a beta of -1.164, suggesting its less volatile than the S&P 500 by 216.414%.
-
Which is a Better Dividend Stock RDY or CCM?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.66%. Concord Medical Services Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Concord Medical Services Holdings Ltd. pays out -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or CCM?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $1B, which are larger than Concord Medical Services Holdings Ltd. quarterly revenues of --. Dr. Reddy's Laboratories Ltd.'s net income of $163.4M is higher than Concord Medical Services Holdings Ltd.'s net income of --. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 17.37x while Concord Medical Services Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.98x versus 0.34x for Concord Medical Services Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.98x 17.37x $1B $163.4M CCMConcord Medical Services Holdings Ltd.0.34x -- -- --
-
Which has Higher Returns RDY or ESPR?
Esperion Therapeutics, Inc. has a net margin of 16.2% compared to Dr. Reddy's Laboratories Ltd.'s net margin of -35.89%. Dr. Reddy's Laboratories Ltd.'s return on equity of 17.11% beat Esperion Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.51.32% $0.20 $4.7B ESPREsperion Therapeutics, Inc.52.71% -$0.16 $146.5M -
What do Analysts Say About RDY or ESPR?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.58, signalling upside risk potential of 2.74%. On the other hand Esperion Therapeutics, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 74.33%. Given that Esperion Therapeutics, Inc. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Esperion Therapeutics, Inc. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 ESPREsperion Therapeutics, Inc.3 1 0 -
Is RDY or ESPR More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.391, which suggesting that the stock is 60.915% less volatile than S&P 500. In comparison Esperion Therapeutics, Inc. has a beta of 1.009, suggesting its more volatile than the S&P 500 by 0.85%.
-
Which is a Better Dividend Stock RDY or ESPR?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.66%. Esperion Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Esperion Therapeutics, Inc. pays out -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or ESPR?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $1B, which are larger than Esperion Therapeutics, Inc. quarterly revenues of $87.3M. Dr. Reddy's Laboratories Ltd.'s net income of $163.4M is higher than Esperion Therapeutics, Inc.'s net income of -$31.3M. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 17.37x while Esperion Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.98x versus 2.42x for Esperion Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.98x 17.37x $1B $163.4M ESPREsperion Therapeutics, Inc.2.42x -- $87.3M -$31.3M
-
Which has Higher Returns RDY or NVO?
Novo Nordisk A/S has a net margin of 16.2% compared to Dr. Reddy's Laboratories Ltd.'s net margin of 26.68%. Dr. Reddy's Laboratories Ltd.'s return on equity of 17.11% beat Novo Nordisk A/S's return on equity of 68.76%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.51.32% $0.20 $4.7B NVONovo Nordisk A/S76.12% $0.70 $42.7B -
What do Analysts Say About RDY or NVO?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.58, signalling upside risk potential of 2.74%. On the other hand Novo Nordisk A/S has an analysts' consensus of $53.27 which suggests that it could grow by 11.31%. Given that Novo Nordisk A/S has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Novo Nordisk A/S is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 NVONovo Nordisk A/S6 3 2 -
Is RDY or NVO More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.391, which suggesting that the stock is 60.915% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.994%.
-
Which is a Better Dividend Stock RDY or NVO?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.66%. Novo Nordisk A/S offers a yield of 3.61% to investors and pays a quarterly dividend of $0.58 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Novo Nordisk A/S pays out 35.93% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or NVO?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $1B, which are smaller than Novo Nordisk A/S quarterly revenues of $11.7B. Dr. Reddy's Laboratories Ltd.'s net income of $163.4M is lower than Novo Nordisk A/S's net income of $3.1B. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 17.37x while Novo Nordisk A/S's PE ratio is 13.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.98x versus 4.57x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.98x 17.37x $1B $163.4M NVONovo Nordisk A/S4.57x 13.94x $11.7B $3.1B
-
Which has Higher Returns RDY or TEVA?
Teva Pharmaceutical Industries Ltd. has a net margin of 16.2% compared to Dr. Reddy's Laboratories Ltd.'s net margin of 9.71%. Dr. Reddy's Laboratories Ltd.'s return on equity of 17.11% beat Teva Pharmaceutical Industries Ltd.'s return on equity of 10.27%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.51.32% $0.20 $4.7B TEVATeva Pharmaceutical Industries Ltd.51.33% $0.37 $24.3B -
What do Analysts Say About RDY or TEVA?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.58, signalling upside risk potential of 2.74%. On the other hand Teva Pharmaceutical Industries Ltd. has an analysts' consensus of $28.61 which suggests that it could grow by 0.52%. Given that Dr. Reddy's Laboratories Ltd. has higher upside potential than Teva Pharmaceutical Industries Ltd., analysts believe Dr. Reddy's Laboratories Ltd. is more attractive than Teva Pharmaceutical Industries Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 TEVATeva Pharmaceutical Industries Ltd.8 2 0 -
Is RDY or TEVA More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.391, which suggesting that the stock is 60.915% less volatile than S&P 500. In comparison Teva Pharmaceutical Industries Ltd. has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.237%.
-
Which is a Better Dividend Stock RDY or TEVA?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.66%. Teva Pharmaceutical Industries Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Teva Pharmaceutical Industries Ltd. pays out -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or TEVA?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $1B, which are smaller than Teva Pharmaceutical Industries Ltd. quarterly revenues of $4.5B. Dr. Reddy's Laboratories Ltd.'s net income of $163.4M is lower than Teva Pharmaceutical Industries Ltd.'s net income of $436M. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 17.37x while Teva Pharmaceutical Industries Ltd.'s PE ratio is 46.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.98x versus 1.95x for Teva Pharmaceutical Industries Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.98x 17.37x $1B $163.4M TEVATeva Pharmaceutical Industries Ltd.1.95x 46.41x $4.5B $436M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
